Angina

Clinical Trial Finder

Many patients with angina are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Fractional FLow Reserve And IVUS for Clinical OUtcomes in Patients With InteRmediate Stenosis

Condition:   Stable Angina
Intervention:   Device: Drug-eluting stent
Sponsors:   Seoul National University Hospital;   Ajou University School of Medicine;   Keimyung University Dongsan Medical Center;   Inje University
Not yet recruiting - verified February 2016

Rivaroxaban ACS Specialist Cohort Event Monitoring Study

Condition:   Acute Coronary Syndrome
Intervention:   Other: This is a non-interventional study
Sponsor:   Drug Safety Research Unit, Southampton, UK
Recruiting - verified February 2016

Knowledge Translation for Patients With Acute Coronary Syndromes

Condition:   Acute Coronary Syndromes
Intervention:   Behavioral: knowledge translation
Sponsors:   Montreal General Hospital;   Sanofi;   Canadian Institutes of Health Research (CIHR);   Fonds de la Recherche en Santé du Québec
Completed - verified January 2016

Timing of Coronary Artery Bypass Surgery Among Patients With Acute Coronary Syndromes Initially on Ticagrelor

Condition:   Acute Coronary Syndrome
Interventions:   Procedure: Early CABG (Day 2-3 after ticagrelor discontinuation);   Procedure: Delayed CABG (Day 5-7 after ticagrelor discontinuation)
Sponsors:   Ottawa Heart Institute Research Corporation;   Canadian Institutes of Health Research (CIHR)
Not yet recruiting - verified January 2016

Hydroxychloroquine in Acute Coronary Syndrome: Prevention of Recurrent Cardiovascular Events

Conditions:   Myocardial Infarction;   Acute Coronary Syndrome;   Inflammation;   Hydroxychloroquine;   Antirheumatic Agents;   Cardiovascular Diseases;   Angina, Unstable
Interventions:   Drug: Hydroxychloroquine;   Drug: Placebo
Sponsors:   Helsinki University Central Hospital;   Finnish Foundation for Cardiovascular Research;   Orion Corporation, Orion Pharma
Not yet recruiting - verified February 2016

Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients

Condition:   Coronary Artery Disease
Interventions:   Drug: Vericiguat (BAY1021189);   Drug: Placebo;   Drug: Nitroglycerin
Sponsors:   Bayer;   Merck Sharp & Dohme Corp.
Recruiting - verified January 2016

Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy

Conditions:   Angina, Stable;   Angina, Unstable;   Anticoagulants
Interventions:   Device: COBRA PzF;   Device: DES
Sponsor:   CeloNova BioSciences, Inc.
Recruiting - verified February 2016

Evaluating Increasing Physical Activity After Hospitalization for Acute Coronary Syndrome

Conditions:   Physical Activity;   Acute Coronary Syndrome
Interventions:   Behavioral: Financial incentive;   Behavioral: Daily feedback
Sponsor:   University of Pennsylvania
Not yet recruiting - verified January 2016

Optilene® Suture for Coronary Artery Bypass Graft Surgery

Conditions:   Coronary Heart Disease;   Multi Vessel Coronary Artery Disease
Intervention:   Procedure: Coronary Artery Bypass Graft surgery
Sponsors:   Aesculap AG;   B.Braun Surgical SA
Recruiting - verified January 2016

ALLiance for sEcondary PREvention After an Episode of Acute Coronary Syndrome (ALLEPRE)

Condition:   Acute Coronary Syndrome
Interventions:   Behavioral: Nurse-led Intensive Secondary Prevention Programme;   Behavioral: Usual Treatment
Sponsor:   Azienda Ospedaliero-Universitaria di Parma
Recruiting - verified February 2016

CER-001 Atherosclerosis Regression ACS Trial

Condition:   Acute Coronary Syndromes
Interventions:   Drug: CER-001;   Drug: Placebo
Sponsors:   Cerenis Therapeutics, SA;   South Australian Health and Medical Research Institute
Recruiting - verified January 2016

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Recruiting - verified January 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsor:   Bayer
Recruiting - verified February 2016

Prospective Registry of Acute Coronary Syndromes in Ferrara

Condition:   Acute Coronary Syndromes
Intervention:   Other: prospective collection of data and follow-up
Sponsor:   University Hospital of Ferrara
Recruiting - verified January 2016

Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients

Condition:   Acute Coronary Syndrome (ACS)
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified February 2016

Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Recruiting - verified February 2016

An Observational Prospective Study to Understand the Usage Pattern of Ticagrelor With ACS (Acute Coronary Syndrome)

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified February 2016

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Condition:   Cost Sharing, Acute Coronary Syndrome,
Intervention:   Other: Study voucher card
Sponsors:   AstraZeneca;   Duke Clinical Research Institute
Recruiting - verified January 2016

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

Conditions:   Coronary Artery Disease;   Atherosclerosis, Coronary;   Myocardial Ischemia;   Ischemic Heart Disease;   Acute Coronary Syndrome;   Angina Pectoris
Interventions:   Device: Orsiro DES;   Device: Xience DES
Sponsors:   Biotronik, Inc.;   Biotronik AG;   Harvard Clinical Research Institute;   Medstar Research Institute
Recruiting - verified February 2016

Screening for Chronic Obstructive Pulmonary Disease in Patients With Acute Coronary Syndromes

Conditions:   Chronic Obstructive Pulmonary Disease;   Acute Coronary Syndromes
Intervention:   Other: screening test
Sponsor:   University Hospital of Ferrara
Active, not recruiting - verified September 2015

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Acetylsalicylic acid;   Drug: Rivaroxaban;   Drug: Clopidogrel;   Drug: Ticagrelor
Sponsors:   Janssen Research & Development, LLC;   Bayer;   Duke Clinical Research Institute;   Harvard Medical School
Recruiting - verified January 2016

Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

Condition:   Hypertrophic Cardiomyopathy
Interventions:   Drug: Eleclazine;   Drug: Placebo
Sponsor:   Gilead Sciences
Recruiting - verified January 2016

Long-term Follow-up of antithrombotIc Management Patterns in Acute Coronary Syndrome Patients in Asia-China Extension

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified January 2016

Exercise as a Life-long Medicine in Patients With Coronary Artery Disease

Conditions:   Cardiovascular Diseases;   Myocardial Infarction;   Angina (Stable)
Interventions:   Behavioral: high-intensity exercise training;   Behavioral: web-based follow-up program;   Behavioral: usual care
Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital;   Levanger Hospital
Recruiting - verified February 2016

Off Pump Versus On Pump Coronary Artery Bypass Grafting in Frailty Patients (FRAGILE)

Conditions:   Coronary Artery Disease;   Complications Due to Coronary Artery Bypass Graft;   Fragility
Interventions:   Procedure: OPCAB;   Procedure: CABG
Sponsors:   University of Sao Paulo General Hospital;   InCor Heart Institute;   Cardiac Emergency Hospital of Pernambuco;   Alberto Urquiza Wanderley Hospital of João Pessoa;   Pitangueiras Hospital of Jundiaí;   University of Campinas, Brazil;   Cardiology Institute of the Distrito Federal;   National Cardiology Institute;   Federal University of São Paulo;   Pontifícia Universidade Católica do Paraná;   Clinical Hospital Samuel Libânio of Pouso Alegre;   Beneficência Portuguesa of São Paulo;   Pontifical University Catholic of Campinas;   InCor Heart Institute of Natal
Not yet recruiting - verified January 2016

Multidetector Coronary CT In Vasospastic Angina

Condition:   Vasospastic Angina
Interventions:   Procedure: Positive CAG with EG test;   Procedure: Negative CAG with EG test
Sponsor:   Dong-A University
Recruiting - verified February 2016

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Epoetin alfa
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified February 2016

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis.

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Placebo
Sponsors:   AstraZeneca;   FibroGen
Active, not recruiting - verified February 2016

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Losmapimod 7.5 mg twice daily;   Drug: Placebo twice daily
Sponsors:   GlaxoSmithKline;   The TIMI Study Group
Recruiting - verified January 2016

Safety and Efficacy Study of Cilostazol to Treat Vasospastic Angina

Condition:   Vasospastic Angina
Intervention:   Drug: Cilostazol
Sponsor:   Korea Otsuka Pharmaceutical Co.,Ltd.
Completed - verified January 2016

Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control

Conditions:   Atrial Fibrillation;   Atrial Flutter
Interventions:   Drug: Metoprolol;   Drug: Diltiazem
Sponsor:   CAMC Health System
Recruiting - verified January 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified January 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified January 2016

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified January 2016

A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)

Condition:   Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Withdrawn - verified February 2016

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Condition:   Prevention & Control
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin;   Drug: Aspirin placebo;   Drug: Rivaroxaban placebo;   Drug: Pantoprazole
Sponsors:   Bayer;   Hamilton Health Sciences Corporation, Population Health Research Institute
Recruiting - verified February 2016

Comparison of Double Kissing Culotte Stenting With Double Kissing Crush Stenting for True Bifurcation Lesions

Condition:   Coronary Heart Disease
Intervention:   Device: Resolute stents
Sponsors:   Fujian Medical University;   Jetmed(Beijing)Co.,Ltd.
Recruiting - verified February 2016

Optical Frequency Domain Imaging (OFDI) and Vascular Healing After Stent Placement Diabetics Presenting With Acute Coronary Syndrome

Condition:   Coronary Artery Disease
Intervention:   Device: Resolute Integrity stent
Sponsor:   Emory University
Active, not recruiting - verified February 2016

A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Omarigliptin;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified January 2016

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab;   Drug: placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified February 2016

A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified January 2016

Coronary Artery Bypass Grafting Strategies for the Anterolateral Territory: a Prospective Randomized Clinical Trial

Condition:   Coronary Artery Disease
Interventions:   Procedure: LIMA to SVG Bridge Technique;   Procedure: Conventional CABG
Sponsors:   Centre hospitalier de l'Université de Montréal (CHUM);   Canadian Institutes of Health Research (CIHR)
Recruiting - verified January 2016

Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery Disease

Condition:   Angina, Stable
Intervention:   Genetic: Alferminogene tadenovec
Sponsors:   Cardium Therapeutics;   Advanced Biosciences Research
Active, not recruiting - verified January 2016

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Coronary Artery Disease;   Heart Diseases;   Myocardial Ischemia
Interventions:   Procedure: cardiac catheterization;   Procedure: coronary artery bypass graft surgery;   Procedure: percutaneous coronary intervention;   Behavioral: Lifestyle;   Drug: Medication
Sponsors:   New York University School of Medicine;   New York University;   Stanford University;   National Heart, Lung, and Blood Institute (NHLBI);   Albany Stratton VA Medical Center;   Cedars-Sinai Medical Center;   Columbia University;   Duke University;   East Carolina University;   Emory University;   Harvard University;   Massachusetts General Hospital;   Montreal Heart Institute;   University of British Columbia;   University of Missouri, Kansas City;   Vanderbilt University
Recruiting - verified January 2016

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Conditions:   Infection;   Hypertension;   Pain;   Reflux;   Edema;   Hyperlipidemia;   Hypotension;   Hypercholesterolemia;   Sedation;   Anxiolysis;   Benzodiazepine Withdrawal;   Bipolar Disorder;   Autistic Disorder;   Schizophrenia;   Influenza Treatment or Prophylaxis;   Acute Decompensated Heart Failure;   Stable Angina;   Life-threatening Fungal Infections;   Nosocomial Pneumonia;   Community Acquired Pneumonia;   Acute Bacterial Exacerbation of Chronic Bronchitis;   Complicated Skin and Skin Structure Infections;   Uncomplicated Skin and Skin Structure Infections;   Chronic Bacterial Prostatitis;   Complicated Urinary Tract Infections;   Acute Pyelonephritis;   Uncomplicated Urinary Tract Infections;   Inhalational Anthrax (Post-Exposure);   Infantile Hemangioma;   Withdrawal;   Inflammation;   Bacterial Septicemia;   Cytomegalovirus Retinitis;   Herpes Simplex Virus;   Adenovirus;   Brain Swelling;   Airway Swelling;   Adrenal Insufficiency;   Anxiety;   Nausea;   Vomiting;   Convulsions;   Muscle Spasms;   Seizures;   Epilepsy;   Bartonellosis;   Brucellosis;   Cholera;   Plague;   Psittacosis;   Q Fever;   Relapsing Fever;   Rocky Mountain Spotted Fever;   Trachoma;   Tularemia;   Typhus Fever;   Bronchospasm;   Cardiac Arrest;   Hypersensitivity Reaction;   Cyanide Poisoning;   Acute Bacterial Sinusitis;   Bacterial Meningitis;   Sepsis;   Gastroparesis;   Opioid Addiction;   Migraines;   Headaches
Intervention:   Drug: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Sponsors:   Daniel Benjamin;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   The EMMES Corporation;   OpAns, LLC
Recruiting - verified February 2016

Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia

Condition:   Microvascular Coronary Dysfunction (MCD)
Interventions:   Drug: Ranolazine;   Drug: Placebo
Sponsors:   Cedars-Sinai Medical Center;   University of Florida
Recruiting - verified January 2016

A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

Condition:   Coronary Heart Disease
Interventions:   Drug: dalcetrapib;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Antidepressants to Promote Recovery of Cardiac Patients Suffering From Depression

Conditions:   Acute Coronary Syndrome;   Major Depressive Episode
Intervention:   Drug: Citalopram
Sponsors:   Centre hospitalier de l'Université de Montréal (CHUM);   Canadian Institutes of Health Research (CIHR);   Centre de Recherche du Centre Hospitalier de l'Université de Montréal;   Montreal Heart Institute
Terminated - verified January 2016

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

Condition:   Coronary Heart Disease
Interventions:   Drug: Evidence-based medical care for Acute Coronary Syndrome;   Drug: Placebo;   Drug: dalcetrapib
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Ischemia Driven Enoxaparin Therapy in ACS Presenting as Low Risk (IDEAL)

Condition:   Unstable Angina
Intervention:   Drug: enoxaparin
Sponsors:   Canadian Heart Research Centre;   Sanofi
Terminated - verified January 2016